ImmunityBio, Inc. IBRX
8.44
(0.20)
(2.31%)
as of 25 Sep
- Market cap
- $9.2B
- P/E
- 0.0×
Follow IBRX
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 122.85% | 117.09% | 71.15% | 55.01% |
+8 more TTM periods Free account |
|
| (192.58%) | (179.83%) | (79.43%) | (78.91%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(208.27%) | (171.67%) | (95.65%) | (86.73%) | |
Average Days of Receivables |
117.72 | 112.03 | 137.16 | 141.55 | |
Free Cash Flow per Share |
(0.27) | (0.29) | (0.34) | (0.34) | |
Free Cash Flow |
(288.07) | (298.89) | (308.78) | (324.76) | |
Capital Expenditures |
(6.94) | (4.50) | (3.85) | (5.05) | |
Piotroski F-Score |
3.00 | 4.00 | 5.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
(327.06%) | (154.83%) | (138.40%) | (135.92%) | |
Accounts Receivable Turnover |
4.39 | 4.68 | 5.04 | 4.56 | |
Accounts Payable Turnover |
0.11 | 0.08 | 0.11 | 0.63 | |
Inventory Turnover |
0.26 | 0.21 | 0.16 | 1.14 | |
Average Days of Payables |
3,999.67 | 4,378.44 | 3,382.43 | 425.17 | |
Days of Inventory on Hand |
646.67 | 213.99 | 441.10 | 493.66 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
147.11% | 169.04% | 192.92% | 230.06% | |
Selling, General and Administrative Expense of Revenue |
104.11% | 115.71% | 132.41% | 185.34% | |
Share Based Compensation of Revenue |
20.70% | 25.14% | 32.49% | 44.94% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.28 | 0.34 | 0.87 | 0.92 | |
Depreciation/Fixed assets |
0.15 | 0.13 | 0.14 | 0.16 | |
Capex/Depreciation |
(0.42) | (0.31) | (0.25) | (0.24) | |
Revenue per Share |
0.16 | 0.14 | 0.12 | 0.09 | |
Operating CF per Share |
(0.27) | (0.29) | (0.33) | (0.34) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | (0.01) | |
Capex to Sales |
0.04 | 0.03 | 0.03 | 0.06 | |
Net Profit Margin |
(598.56%) | (606.15%) | (310.18%) | (422.28%) |
Columns are period end dates